Background
Malawi implemented 6-multi-month dispensing (6MMD) of antiretroviral therapy (ART) for clinically stable clients on HIV treatment during 2019 and scaled-up implementation in 2020. We compared retention for clients who received 6MMD to those who did not receive 6MMD and assessed predictors of retention.
Methods
We applied a target trial emulation (TTE) approach using routine clinical data from Malawi’s Electronic Medical Record (EMR) system to identify ART clients eligible for 6MMD in 27 districts from 01/2020-12/2021. Eligible participants were non-pregnant adults ≥18 and on ART for ≥6 months with no prior 6MMD exposure. We created four six-month trials, defining eligibility at the start of each period and classifying participants as either receiving 6MMD or non-6MMD (dispensing duration of 1-3 months). We defined the follow-up start date as the 6MMD enrollment date for the 6MMD arm and the first visit in the trial enrollment period for the non-6MMD arm. Retention at 12 and 24 months were defined as having a clinic visit within 12-24 (Trial 1-4) and 24-36 (Trial 1-2) months. Using an intention-to-treat approach, we estimated risk differences (RD) with 95% confidence intervals (CI) using a Poisson regression model with an identity link function and robust standard errors. Pooled RD were estimated by accounting for within-subject variation in a Poisson regression model using data from all trials.
Results
Of the 287,933 unique individuals eligible for this study (57% female, median age 41), 73% (212,722) were enrolled in 6MMD. Retention at 12 months (Trials 1-4) and 24 months (Trials 1-2) were consistently higher in the 6MMD group than in the non-6MMD group. The pooled risk difference (RD) for retention between the 6MMD and non-6MMD groups was 4.6% (95% CI: 4.4-4.8) at 12 months (Figure 1) and 4.7% (95% CI: 4.4-5.0) at 24 months. Across all trials, retention was higher for females; those aged 25years and older; those with mild HIV disease (WHO Stage 1/2 at ART initiation), those receiving care at primary health care clinics, and those on ART longer at trial start.
Conclusions
We observed slightly higher retention in care rates in Malawi at 12 and 24 months among clients on 6MMD compared to those receiving shorter medication dispensing intervals. Future work to assess the impact of 6MMD on visit burden and resource use would offer a comprehensive view of the benefits to both ART clients and the health system.